Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from MustGrow Biologics ( (TSE:MGRO) ) is now available.
MustGrow Biologics Corp. reported record Q3-2025 financial results, with sales revenue reaching $0.8 million, marking a significant improvement from no revenue in the same quarter of the previous year. The company’s gross profit margin increased to 22.9%, driven by higher margin product sales through its NexusBioAg division. MustGrow is optimistic about stronger sales in Q4 and Q1-2026 as farmers prepare for the upcoming growing season, and it continues to focus on revenue growth through its Canadian and U.S. business operations.
Spark’s Take on TSE:MGRO Stock
According to Spark, TipRanks’ AI Analyst, TSE:MGRO is a Neutral.
MustGrow Biologics’ overall stock score of 57 reflects significant revenue growth and strategic market expansions, countered by ongoing financial challenges and valuation concerns. The company’s strong gross margins and low leverage are positives, but the persistent net losses and negative cash flow remain crucial risks.
To see Spark’s full report on TSE:MGRO stock, click here.
More about MustGrow Biologics
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions aimed at supporting sustainable farming. The company offers eco-friendly alternatives to synthetic chemicals and fertilizers, with a focus on North American crop nutrition solutions and international collaborations to commercialize its proprietary products.
Average Trading Volume: 20,345
Technical Sentiment Signal: Sell
Current Market Cap: C$29.34M
For detailed information about MGRO stock, go to TipRanks’ Stock Analysis page.